Ironwood Pharmaceuticals | IRWD - Cash And Equivalent


Ironwood Pharmaceuticals reported $140.41M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amarin USD 122.8M 25.08M Sep/2025
Ardelyx USD 42.72M 47.32M Sep/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Charles River Laboratories USD 207.1M 24.27M Sep/2025
Exact Sciences USD 789.04M 131.94M Sep/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Moderna USD 1.13B 147M Sep/2025
Myriad Genetics USD 145.4M 71M Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Takeda JPY 654.94B 26.55B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025